Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hygeia Sciences was a pioneering biotechnology company based in Newton, Massachusetts, that revolutionized the home diagnostics market in the 1980s. Founded by Dr. Irving Berstein and Dr. Lovick Edward Cannon, the company was among the first to apply monoclonal antibody technology to consumer healthcare products. Its most significant achievement was the development of the "First Response" brand of one-step pregnancy and ovulation predictor tests, which offered unprecedented accuracy and speed for over-the-counter use. In 1987, the company was acquired by Tambrands for $47.8 million to complement its Tampax product line, and it was subsequently sold to Carter-Wallace in 1989. The technology developed by Hygeia Sciences laid the foundation for modern rapid diagnostic testing and established monoclonal antibodies as a viable tool for mass-market diagnostics.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hygeia Sciences.